BRCA2 and endometrial cancer: Debate, therefore, continues within the scientific and medical communities as to whether risk-reducing hysterectomy should be offered to women with BRCA1 and BRCA2 pathogenic variants at the time of their RRSO to reduce their subsequent endometrial cancer risk[11,15].